947249-13-0

Basic information

• Product Name: 5-Bromo-3-(difluoromethoxy)pyridin-2-amine
• Synonyms: 5-Bromo-3-(difluoromethoxy)pyridin-2-amine;5-bromo-3-(difluoromethoxy)-2-Pyridinamine;5-Bromo-3-(difluoromethoxy)
• CAS NO: 947249-13-0
• Molecular Formula: C6H5BrF2N2O
• Molecular Weight: 239.02
• EINECS: 1592732-453-0
• Mol File: 947249-13-0.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 248.9±35.0 °C(Predicted)
• Appearance: /
• Density: 1.752
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 4.85±0.10(Predicted)
• CAS DataBase Reference: 5-Bromo-3-(difluoromethoxy)pyridin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-3-(difluoromethoxy)pyridin-2-amine(947249-13-0)
• EPA Substance Registry System: 5-Bromo-3-(difluoromethoxy)pyridin-2-amine(947249-13-0)

Safety Data

• Hazardous Substances Data: 947249-13-0(Hazardous Substances Data)

Usage

Description

5-Bromo-3-(difluoromethoxy)pyridin-2-amine is a chemical compound characterized by the presence of a pyridine ring with a bromine atom at the 5th position, a difluoromethoxy group at the 3rd position, and an amine group at the 2nd position. 5-bromo-3-(difluoromethoxy)pyridin-2-amine is known for its potential applications in the synthesis of various pharmaceutically relevant molecules.

Uses

Used in Pharmaceutical Industry:
5-Bromo-3-(difluoromethoxy)pyridin-2-amine is used as a key intermediate in the synthesis of imidazo[1,2-a]pyridinyl derivatives. These derivatives have shown promising therapeutic potential in the treatment of various diseases, making them valuable candidates for drug development.
In the preparation of imidazo[1,2-a]pyridinyl derivatives, 5-bromo-3-(difluoromethoxy)pyridin-2-amine serves as a building block, allowing for the creation of diverse chemical structures with potential medicinal properties. The incorporation of this compound into the synthesis process contributes to the development of novel therapeutic agents that can address unmet medical needs and improve patient outcomes.

Upstream product

• 75-45-6 Chlorodifluoromethane 
• 39903-01-0 2-amino-3-hydroxy-5-bromopyridine 
• 15128-82-2 3-hydroxy-2-nitropyridine 
• 1111637-77-4 3-(difluoromethoxy)-2-nitropyridine 
• 947249-27-6 2-bromo-3-(difluoromethoxy)pyridine 
• 6602-32-0 2-bromo-pyridin-3-ol 
• 947249-14-1 3-(difluoromethoxy)pyridin-2-amine 

Downstream Products

• 1188302-00-2 3-(difluoromethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine 

Relevant articles and documents

SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF

The present disclosure relates to novel compounds including formula (X) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.

PYRAZOLE DERIVATIVES AND USES THEREOF AS INHIBITORS OF DLK

The present invention provides for compounds of formula 0 and various embodiments thereof, and compositions comprising compounds of formula 0 and various embodiments thereof. In compounds of formula 0, the groups R1A, R1B, R1C, R1D, R2, R3, R4, R5 and R6 have the meaning as described herein. The present invention also provides for methods of using compounds of formula 0 and compositions comprising compounds of formula 0 as DLK inhibitors and for treating neurodegeneration diseases and disorders.

3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS

The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. (I) In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6 and R7 have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.